Eur J Med Res . The outcome of using intravenous immunoglobulin (IVIG) in critically ill COVID-19 patients': a retrospective, multi-centric cohort study

[tetano]

Eur J Med Res


. 2022 Feb 3;27(1):18.
doi: 10.1186/s40001-022-00637-8.
The outcome of using intravenous immunoglobulin (IVIG) in critically ill COVID-19 patients': a retrospective, multi-centric cohort study


Mohammadreza Salehi ¹ , Mahdi Barkhori Mehni ² , Mohammadmehdi Akbarian ² , Samrand Fattah Ghazi ³ , Nasim Khajavi Rad ⁴ , Omid Moradi Moghaddam ⁵ , SaeedReza Jamali Moghaddam ⁶ , Masoumeh Hosseinzadeh Emam ⁷ , Sayed Hamidreza Abtahi ⁸ , Maryam Moradi ⁹ , Fereshteh Ghiasvand ¹⁰



Affiliations

• PMID: 35115056
• DOI: 10.1186/s40001-022-00637-8

Abstract

Background: During the COVID-19 pandemic, different treatments have been used in critically ill patients. Using intravenous immunoglobulin (IVIG) has been suggested in various studies as an effective option. Our study aims to access the efficacy of IVIG in critically ill COVID-19 patients.
Methods: In this retrospective matched cohort study, records of three tertiary centers with a large number of COVID-19 admissions were evaluated and used. Based on treatment options, patients were divided into two groups, standard COVID-19 treatment (109 patients) and IVIG treatment (74 patients) patients. Also, the effect of IVIG in different dosages was evaluated. Patients with IVIG treatment were divided into three groups of low (0.25 gr/kg), medium (0.5 gr/kg), and high (1 gr/kg) dose. Data analysis was performed using an independent t test and one-way analysis of variance (ANOVA) to compare the outcomes between two groups, including duration of hospitalization, intensive care unit (ICU) length of stay, and mortality rate.
Results: The duration of hospitalization in the IVIG group was significantly longer than standard treatment (13.74 days vs. 11.10 days, p < 0.05). There was no significant difference between the two groups in ICU length of stay, the number of intubated patients, and duration of mechanical ventilation (p > 0.05). Also, initial outcomes in IVIG subgroups were compared separately with the standard treatment group. The results indicated that only the duration of hospitalization in the IVIG subgroup with medium dose is significantly longer than the standard treatment group (p < 0.01).
Conclusion: Our data indicate that the use of IVIG in critically ill COVID-19 patients could not be beneficial, based on no remarkable differences in duration of hospitalization, ICU length of stay, duration of mechanical ventilation, and even mortality rate.

Keywords: COVID-19; Coronavirus; IVIG; Intravenous immunoglobulin; Pandemic; Pneumonia.